What is the appropriate management for arachnoiditis?

Management of Arachnoiditis

For acute or subacute arachnoiditis (within 10 days of onset), initiate high-dose corticosteroids immediately; for chronic adhesive arachnoiditis, consider surgical microdissection with ventriculo-subarachnoid shunting in selected cases with severe symptoms, while managing chronic pain with neuropathic agents like gabapentin, pregabalin, or duloxetine. 1, 2

Acute and Subacute Arachnoiditis Management

Corticosteroid Therapy

• Initiate methylprednisolone 1-2 mg/kg IV for acute presentations 2, 1
• For severe or rapidly progressing symptoms, consider pulse-dose methylprednisolone 1 g IV daily for 3-5 days 2
• Oral prednisone regimens have shown good outcomes when initiated within 10 days of symptom onset 1
• Early corticosteroid treatment (within 10 days) appears critical for preventing progression to chronic adhesive disease 1

Diagnostic Workup Requirements

• MRI of spine with and without contrast using thin axial cuts through affected regions 2
• Lumbar puncture to assess: cell count, protein, glucose, oligoclonal bands, viral PCRs, cytology, and onconeural antibodies 2
• Blood work: B12, HIV, rapid plasma reagin, ANA, Ro/La, TSH, aquaporin-4 immunoglobulin G 2
• Evaluate for urinary retention and constipation 2

Additional Acute Management Considerations

• Permanently discontinue any immune checkpoint inhibitors if drug-induced 2
• Consider IVIG 2 g/kg over 5 days if limited improvement with corticosteroids alone 2
• Neurology consultation is essential for all cases 2

Chronic Adhesive Arachnoiditis Management

Surgical Approaches

For patients with severe, disabling symptoms and documented spinal cord tethering or CSF flow disturbance:

• Arachnoid microdissection (microlysis) to resolve spinal cord tethering 3, 4
• Ventriculo-subarachnoid shunt placement to restore adequate CSF flow 3
• Spondylodesis (spinal fusion) following microlysis improves outcomes to 80% success rate versus 54.8% with microlysis alone 4
• Mini-invasive intrathecal endoscopic adhesiolysis may reduce risk of aggravating inflammation compared to open surgical approaches 5

Medical Management for Chronic Pain

• Offer gabapentin, pregabalin, or duloxetine as first-line neuropathic pain agents 2
• Analgesics including acetaminophen and opioid medications may be considered for residual pain when other treatments fail 2
• NSAIDs can be used for inflammatory pain components, weighing cardiovascular, gastrointestinal, and renal risks 2

Postinfectious Arachnoiditis Specific Considerations

• Rule out ongoing infection with appropriate cultures and antimicrobial therapy before immunosuppression 2
• For subarachnoid involvement, anti-inflammatory therapy should be initiated prior to any antiparasitic drugs if infectious etiology confirmed 2
• Consider methotrexate as steroid-sparing agent for patients requiring prolonged anti-inflammatory therapy 2

Critical Pitfalls to Avoid

Infection Risk Management

• Remove intrathecal catheters at earliest opportunity post-delivery or procedure to minimize infectious complications 2
• If accidental catheter disconnection occurs, remove immediately due to increased infection risk 2
• Maintain strict aseptic technique; contamination from nasopharynx or skin organisms can cause meningitis 2
• Monitor for CSF-cutaneous fistula formation, which creates direct route for microbial entry 2

Surgical Timing Considerations

• Conservative management may be appropriate for mild myelopathy symptoms 5
• Lumbar drainage should be considered early in subarachnoid hemorrhage cases to clear blood products and prevent inflammatory cascade 5
• Surgical debulking may benefit select patients with hydrocephalus beyond shunt surgery alone 2

Monitoring Requirements

• Evaluate for urinary retention and constipation throughout treatment course 2
• Assess for development of syringomyelia as major complication requiring separate intervention 6
• No consensus exists on optimal management due to variable disease presentation; individualize based on symptom severity, location, and degree of arachnoiditis 2, 6